Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-peptide response to intravenous glucagon

No abstract is available for this paper.

• Publication year

  1977

• Venue

  Diabetologia

• Publication date

  1977-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF01236316PMID 338408
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• B-cell function and blood glucose control in insulin dependent diabetics within the first month of insulin treatment

  1977cited by this paper
• C-peptide Response to Glucagon: A Test for the Residual β-cell Function in Diabetes Mellitus

  1977cited by this paper
• Control of juvenile diabetes mellitus and its relationship to endogenous insulin secretion as measured by C-peptide immunoreactivity.

  1977cited by this paper
• Production of antisera to synthetic benzyloxycarbonyl-C-peptide of human proinsulin.

  1976cited by this paper
• Human C-peptide

  1976cited by this paper
• C-Peptide in children with juvenile diabetes

  1976cited by this paper
• Radioimmunological determination of human C-peptide in serum

  1975cited by this paper
• Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood.

  1975cited by this paper
• Identification of proinsulin and C-peptide in human serum by a specific immunoassay.

  1970cited by this paper

• Islet Function and Insulin Sensitivity in Latent Autoimmune Diabetes in Adults Taking Sitagliptin: A Randomized Trial

  2021cites this paper
• The impact of flash glucose monitoring on glycemic control varies with the age and residual beta-cell function of patients with type 1 diabetes mellitus.

  2021cites this paper
• Fasting C-peptide Levels as Predictor Marker for Type1 Diabetes Mellitus among Diabetic Children at Khartoum State

  2019cites this paper
• Circulating anti‐glutamic acid decarboxylase‐65 antibody titers are positively associated with the capacity of insulin secretion in acute‐onset type 1 diabetes with short duration in a Japanese population

  2019cites this paper
• Insulin sensitivity and secretion and adipokine profile in patients with Cushing’s disease treated with pasireotide

  2018cites this paper
• The BETA-2 Score: a Tool for Assessing Beta Cell Function in Clinical Islet Transplantation and Type 1 Diabetes Intervention Trials

  2017cites this paper
• C-Peptide Level in Fasting Plasma and Pooled Urine Predicts HbA1c after Hospitalization in Patients with Type 2 Diabetes Mellitus

  2016cites this paper
• Utility of C-peptide for a reliable estimate of insulin secretion in children with growth hormone deficiency.

  2016cites this paper
• Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylurea-combination therapy in Japanese type 2 diabetes: Association of remaining β-cell function and achievement of HbA1c target one year after initiation.

  2015cites this paper
• Early liraglutide treatment improves β-cell function in patients with type 2 diabetes: a retrospective cohort study.

  2015cites this paper
• Evaluation of Long-Term Treatment Effect in a Type 1 Diabetes Intervention Trial: Differences After Stimulation With Glucagon or a Mixed Meal

  2014cites this paper
• Age‐dependent decline of β‐cell function in type 1 diabetes after diagnosis: a multi‐centre longitudinal study

  2014cites this paper
• The area of abdominal subcutaneous adipose tissue is independently correlated with C-peptide increment during glucagon load in Japanese patients with type 2 diabetes

  2013cites this paper
• Retrospective analysis of safety and efficacy of insulin‐to‐liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β‐cell function

  2013cites this paper
• Analysis of clinical factors contributing to the postglucagon increment in C-peptide levels in Japanese patients with type 2 diabetes: comparison with basal C-peptide levels and 24-h urinary C-peptide excretion

  2013cites this paper
• Lessons From the Mixed-Meal Tolerance Test

  2013cites this paper
• Use of 90-minute and fasting C-peptide in pediatric diabetes

  2012cites this paper
• Effectiveness of the glucagon test in estimating islet function for liraglutide treatment in a lean diabetic patient with impaired insulin response to glucose

  2012cites this paper
• The impact of insulin administration during the mixed meal tolerance test

  2012cites this paper
• Utility of indices using C‐peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patients with type 2 diabetes

  2011cites this paper
• Analysis of factors influencing postprandial C‐peptide levels in Japanese patients with type 2 diabetes: Comparison with C‐peptide levels after glucagon load

  2011cites this paper
• Age-dependent relationship of fasting C-peptide concentration and insulin secretion in non-obese subjects with normal glucose tolerance.

  2009cites this paper
• Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus.

  2009cites this paper
• Outcome of the glucagon test depends upon the prevailing blood glucose concentration in type I (insulin-dependent) diabetic patients.

  2009cites this paper
• Factors of importance for residual beta-cell function in type I diabetes mellitus. A review.

  2009cites this paper
• Diagnostic performance of the ARCHITECT C-Peptide immunoassay

  2009cites this paper
• 5-Year Follow-up Study of C-Peptide Secretion in Newly Diagnosed Type I Diabetics: Relations to HLA- Phenotype, Insulin Requirement and Metabolic Control

  2009cites this paper
• Residual C-peptide production in type I diabetes mellitus. A comparison of different methods of assessment and influence on glucose control.

  2009cites this paper
• Factors associated with improvement of fasting plasma glucose level by mealtime dosing of a rapid-acting insulin analog in type 2 diabetes.

  2007cites this paper
• Residual Beta-Cell Metabolic Stability Diabetes Mellitus Function and in Insulin-Dependent

  2006cites this paper
• Influence of exogenous insulin on C-peptide levels in subjects with type 2 diabetes.

  2005cites this paper
• Immunological abnormalities in islets at diagnosis paralleled further deterioration of glycaemic control in patients with recent-onset Type I (insulin-dependent) diabetes mellitus

  1999cites this paper
• Persistent GAD 65 antibodies in longstanding IDDM are not associated with residual beta-cell function, neuropathy or HLA-DR status.

  1997cites this paper
• The C-peptide response to a standard mixed meal in a group of Brazilian type 1 diabetic patients.

  1997cites this paper
• Natural course of growth hormone hypersecretion in insulin-dependent diabetes mellitus.

  1996cites this paper
• Renal metabolism of C-peptide in patients with early insulin-dependent diabetes mellitus.

  1996cites this paper
• The remission concept in type 1 diabetes and its significance in immune intervention.

  1993cites this paper
• Association of HLA-A24 with complete beta-cell destruction in IDDM.

  1993cites this paper
• Pancreatic B‐cell functioning after intravenous glucagon administration in anorexia nervosa

  1992cites this paper
• C-peptide response to oral glucose and its clinical role in elderly people.

  1992cites this paper
• C-peptide used in the estimation of islet beta-cell function in diabetes.

  1992cites this paper
• Factors predicting residual beta-cell function in the first year after diagnosis of childhood type 1 diabetes.

  1991cites this paper
• Vitreous fluorophotometry in juvenile diabetics with and without retinopathy in relation to metabolic control: Insulin antibodies and c‐peptide levels

  1990cites this paper
• Deleterious effect of anti-insulin antibodies on diabetes control.

  1990cites this paper
• Relationships among islet cell antibodies, residual beta-cell function, and metabolic control in patients with insulin-dependent diabetes mellitus of long duration: use of a sensitive C-peptide radioimmunoassay.

  1990cites this paper
• Fasting plasma C-peptide, glucagon stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes

  1989cites this paper
• Sensitivity and Reproducibility of Urinary C‐peptide as Estimate of Islet B‐cell Function in Insulin‐treated Diabetes

  1989cites this paper
• Factors Associated With Fasting and Postglucagon Plasma C-Peptide Levels in Middle-Aged Insulin-Treated Diabetic Patient

  1989cites this paper
• Glucagon-Stimulated and Postprandial Plasma C-Peptide Values as Measures of Insulin Secretory Capacity

  1988cites this paper
• Metabolic effects of continuous subcutaneous insulin infusion: evidence that a rise and fall of portal vein insulin concentration with each major meal facilitates post-absorptive glycemic control.

  1988cites this paper
• Correlation Between Minimal Secretory Capacity of Pancreatic β-Cells and Stability of Diabetic Control

  1988cites this paper
• Residual beta-cell function and metabolic stability in insulin-dependent diabetes mellitus.

  1988cites this paper
• Reproducibility of the Glucagon Test

  1987cites this paper
• Insulin resistance in maturity onset diabetes of the young.

  1987cites this paper
• Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus.

  1987cites this paper
• Factors affecting and patterns of residual insulin secretion during the first year of Type 1 (insulin-dependent) diabetes mellitus in children

  1987cites this paper
• Residual beta-cell function in children with IDDM: reproducibility of testing and factors influencing insulin secretory reserve.

  1987cites this paper
• Practical aspects in performing the glucagon test in the measurement of C-peptide secretion in diabetic patients.

  1986cites this paper
• Current approaches to measurement of insulin secretion.

  1986cites this paper
• The Effect of Residual Beta‐cell Function on the Development of Diabetic Retinopathy

  1986cites this paper
• Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients.

  1986cites this paper
• Ingestion of a mixed meal does not affect the metabolic clearance rate of biosynthetic human C-peptide.

  1986cites this paper
• Somatostatin response to a mixed meal in normals and in type I diabetics.

  1986cites this paper
• Discrimination of type I from insulin-treated type II diabetic patients by C-peptide measurement

  1986cites this paper
• Plasma and urinary C-peptide in the classification of adult diabetics.

  1986cites this paper
• [Glucagon test: criterion for insulin therapy in type II diabetes mellitus].

  1985cites this paper
• A comparison of serum C-peptide response to intravenous glucagon, and urine C-peptide, as indexes of insulin dependence.

  1985cites this paper
• C-peptide determination in the choice of treatment in diabetes mellitus.

  1985cites this paper
• Pathophysiology of insulin secretion in diabetes mellitus.

  1985cites this paper
• C-peptide measurement in the differentiation of Type 1 (insulin-dependent) and Type 2 (non-insulin-dependent) diabetes mellitus

  1985cites this paper
• Continuous Subcutaneous Insulin Infusion in Adults: Glycemic Advantage is Predicted by Venous Plasma C-Peptide Concentrations

  1985cites this paper
• Urine C-peptide in relation to the degree of insulin dependence in diabetic patients.

  1985cites this paper
• C-peptide measurement: methods and clinical utility.

  1984cites this paper
• C-peptide and free insulin determinations in type I diabetes; relationships with metabolic control and insulin therapy.

  1984cites this paper
• Improved diabetic control in insulin-dependent diabetics treated with insulin and glibenclamide.

  1984cites this paper
• Plasma C‐peptide Levels Identify Insulin‐treated Diabetic Patients Suitable for Oral Hypoglycaemic Therapy

  1984cites this paper
• Diabetic retinopathy: a review of general medical factors in patient care.

  1984cites this paper
• Residual B-cell function in type 1 (insulin-dependent) diabetes mellitus: Its relation to clinical and metabolic features

  1984cites this paper
• [Insulin reserve of insulin-dependent diabetics. Role of C-peptide in the hormonal balance in diabetes].

  1983cites this paper
• [Basal C peptide levels in response to intravenous tolbutamide in the detection of incorrect insulin therapy (or prolonged misuse)].

  1983cites this paper
• Prevalence of residual B cell function and its metabolic consequences in Type 1 (insulin-dependent) diabetes

  1983cites this paper
• Residual B-cell function in insulin dependent (Type 1) and non insulin-dependent (Type 2) diabetics (relationship between 24-hour C-peptide excretion and the clinical features of diabetes).

  1983cites this paper
• Correlation between fasting serum C-peptide and B cell insulin secretory capacity in diabetes mellitus

  1982cites this paper
• [Diabetic microangiopathy and B-cell residual function. Studies in patients with long-term diabetes mellitus].

  1982cites this paper
• Insulin Antibodies in Juvenile Diabetes Mellitus

  1982cites this paper
• B cell function in patients with chronic pancreatitis and its relation to exocrine pancreatic function

  1982cites this paper
• Kinetic Analysis of the Response of Plasma Glucose, Insulin, and C-Peptide to Glucagon Injection in Normal and Diabetic Subjects

  1981cites this paper
• The relationship between residual insulin secretion and metabolic stability in Type 1 (insulin dependent) diabetes

  1981cites this paper
• Failure of indomethacin to affect arginine-induced C-peptide and glucagon release in insulin-treated diabetics

  1981cites this paper
• Residual beta-cell function and islet cell antibodies in diabetic children.

  1981cites this paper
• Plasma C-peptide in long-standing type 1 diabetics with and without microvascular disease.

  1981cites this paper
• The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects.

  1981cites this paper
• C-Peptide Measurement and its Clinical Usefulness: A Review

  1981cites this paper
• Development of bone mineral loss in insulin‐treated diabetes: a 1 1/2 years follow‐up study in sixty patients

  1981cites this paper
• C-peptide-measurement: a simple method for the improvement of specificity.

  1981cites this paper
• Effect of strict blood glucose control on residual B-cell function in insulin-dependent diabetics

  1981cites this paper
• Beta-cell function and metabolic control in insulin treated diabetics.

  1980cites this paper
• Residual β cell function in insulin-dependent diabetes: evaluation by circadian determination of C-peptide immunoreactivity

  1980cites this paper
• [Long-term follow-up study of C-cell-function after partial duodenopancreatectomy (author's transl)].

  1980cites this paper
• [The clinical value of C-peptide assay (author's transl)].

  1980cites this paper